SAB Biotherapeutics Inc — Quarterly Cash Flow (NASDAQ:SABS)

Financials

Total assets 44.2 M38.12 M30.13 M183.45 M172.81 M Total liabilities 18.23 M16.71 M18.11 M18.37 M21.32 M Total equity 25.97 M21.41 M12.02 M165.07 M151.49 M Total liabilities & shareholders' equities 44.2 M38.12 M30.13 M183.45 M172.81 M Total debt 418.41 K3 M2.81 M2.87 M2.52 M Net debt -20.34 M-9.85 M-2.9 M-108.01 M-94.07 M

뉴스

H.C. Wainwright, SAB 바이오테라퓨틱스 목표가 7달러로 하향

H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution

SAB 바이오테라퓨틱스, 1상 시험서 초기 C-펩타이드 신호 보고

SAB Biotherapeutics reports early C-peptide signals in phase 1 trial

SAB Biotherapeutics, UBS ’매수’ 등급 개시…당뇨병 치료제 잠재력

SAB Biotherapeutics stock initiated with Buy rating at UBS on diabetes drug potential

구겐하임, SAB 바이오테라퓨틱스에 ’매수’ 등급 제시, T1D 잠재력 주목

Guggenheim initiates SAB Biotherapeutics stock with Buy rating on T1D potential

SAB Biotherapeutics, 이사진 사임 후 이사회 규모 축소

SAB Biotherapeutics reduces board size following resignations of two directors

SAB Biotherapeutics, 주주, 지분 계획 수정안 승인

SAB Biotherapeutics shareholders approve equity plan amendment and Series B conversion proposal